profit from every $100 of sales.
$0$100
Grace Therapeutics
$1.81+0.00% today
-41.6% in 1 year
1-year low $1.781-year high $5.13
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Grace Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$9.57 million of profit last year.
SalesProfit
Grace Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Grace Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Grace Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| 0 | – | – | – | |
| -15 | -18 | -11 | -17 | |
| -15 | -18 | -11 | -17 | |
| -10 | -42 | -13 | -10 | |
| -1.62 | -5.71 | -1.35 | -0.79 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 129 | 79 | 73 | 72 |
| Cash | 30 | 28 | 23 | 22 |
| Total debt | 0 | 0 | 0 | – |
| Total liabilities | 20 | 11 | 12 | 5 |
| 108 | 68 | 62 | 67 | |
| 6 | 7 | 10 | 12 | |
| -11.2% | -21.1% | -14.5% | -19.8% | |
| -9.1% | -62.4% | -20.8% | -14.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -17 | -16 | -12 | -15 | |
| – | 0 | 0 | – | |
| -17 | -16 | -12 | -15 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 2 | 1 | 1 |
Valuation
- –
- –
- –
- 0.6×
- –
- –
- –
- -39.1%
- -25.1%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -15.8%
- -28.3%
- -10.6%
- -10.0%
- -18.1%
- –
Growth
- –
- –
- −20.6%
- –
- +48.7%
Financial health
- -2.4×
- 0.00
- 0.0%
- –
- 14.96
- 14.96
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 952
Bottom 20%of 883
Bottom 1%of 987
What analysts expect
- Average price target
- $4.00
- Range
- $4.00 – $4.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 12, 2026 | -0.14 | -0.09 | −55.6% |
| Nov 13, 2025 | -0.15 | -0.12 | −25.0% |
| Aug 12, 2025 | -0.21 | -0.22 | +4.5% |
| Jun 23, 2025 | -0.21 | -0.20 | −5.0% |
| Feb 13, 2025 | -0.26 | -0.24 | −8.3% |
| Nov 13, 2024 | -0.33 | -0.33 | +0.0% |
| Aug 9, 2024 | -0.24 | -0.28 | +14.3% |
| Jun 21, 2024 | -0.18 | -0.35 | +48.6% |
News
Jensen Huang Says Nvidia's Next-Gen Vera Rubin Chips Will Generate $40 Billion in Revenue per Gigawatt, Up From $25 Billion for Grace Blackwell. What That Means for Nvidia's Growth Runway?Yahoo Finance · Nov 6, 2026Jensen Huang Says Nvidia's Next-Gen Vera Rubin Chips Will Generate $40 Billion in Revenue per Gigawatt, Up From $25 Billion for Grace Blackwell. What That Means for NVDA's Growth Runway.Yahoo Finance · Oct 26, 2026Jensen Huang Declares “AGI Has Arrived” — Powered by 100,000+ Nvidia Grace Blackwell GPUsYahoo Finance · Sep 7, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
72Pass
Philip Fisher
35No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
34No pass
Questions about Grace Therapeutics
Is Grace Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Grace Therapeutics AI analysis
What does Grace Therapeutics do?
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It is in Biotechnology.
Does Grace Therapeutics pay a dividend?
No. Grace Therapeutics does not pay a dividend at the moment.
Is Grace Therapeutics stock halal?
No. Grace Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 58% of its market value, at or above the 33% limit. How we check
How has Grace Therapeutics stock done over the past year?
Down 41.6% over the past twelve months, to $1.81. It traded between $1.78 and $5.13 and is 64.7% below its high.
Who are Grace Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Grace Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.